News
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership
Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Poxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-News: Abivax announces its ordinary and extraordinary general meeting of June 5, 2023, and the availability of the preparatory documents
Savara Reports First Quarter Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2023 and provided a
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Poxel Announces Upcoming Participation at the JMP Securities Life Science Conference
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Transgene provides business update and Q1 2023 financial position
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides a business update, including
Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the first patient has been
EQS-News: Formycon Announces Participation in International Investor Conferences in Q2/2023
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced data from the kidney biopsy sub-study of the AURORA clinical trial program (AURORA 1 and AURORA 2 Extension
IMV Receives NASDAQ Delisting Notice
IMV Inc. (the “Company” or “IMV”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat
Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Annual General Meeting of Kuros Biosciences approves all resolutions
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On May 3, 2023
Transgene’s Combined General Meeting of May 5, 2023
Regulatory News:
The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 5, 2023) at 9:00 a.m. at the Company’s headquarters (400
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that the Board has appointed Dr Alessandro
Evolva signs multi-year agreement with leading CMO partner to enable supply of Vanillin to global F&F customer of around CHF 35 million until 2026
Puma Biotechnology Reports First Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2023. Unless otherwise stated, all comparisons are for the
EQS-News: Abivax publishes Universal Registration Document 2023 “Document d’Enregistrement Universel”
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars.
Total net
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS® (voclosporin) as an
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization of LUPKYNIS®